Alphavirus Encephalomyelitis: Mechanisms and Approaches to Prevention of Neuronal Damage

Diane E Griffin1

  • 1W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA. dgriffi6@jhu.edu.

Insights

Treating Sindbis virus infection with specific glutamate receptor antagonists protected neurons and prevented death in mice. This protection was linked to reduced immune response and inflammation in the central nervous system.

Area of Science:

  • Neuroscience
  • Immunology
  • Virology

Background:

  • Mosquito-borne viruses cause encephalomyelitis, leading to death and neurological disability.
  • Neuronal susceptibility to virus infection and death varies with age, genetics, and virus virulence.
  • In mature mice, the hippocampus and spinal cord motor neurons are most vulnerable, causing memory deficits and paralysis.

Purpose of the Study:

  • To investigate neuroprotective strategies against Sindbis virus-induced encephalomyelitis.
  • To evaluate the efficacy of glutamate excitotoxicity modulators in preventing neuronal damage and mortality.
  • To understand the role of immune-mediated damage in disease outcome.

Main Methods:

  • Mice were infected with Sindbis virus.
  • Treated with N-methyl-D-aspartate receptor antagonist (MK-801), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonists (GYKI-52466, talampanel), or a glutamine antagonist (6-diazo-5-l-norleucine).
  • Assessed neuronal protection, survival rates, memory function, and central nervous system inflammation.

Main Results:

  • AMPA receptor antagonists protected both hippocampal and motor neurons, preventing paralysis and death.
  • N-methyl-D-aspartate receptor antagonist protected hippocampal neurons but not motor neurons.
  • Glutamine antagonist improved memory in surviving mice infected with avirulent virus.
  • Protection correlated with reduced antiviral immune response, decreased inflammatory cell infiltration, and delayed viral clearance.

Conclusions:

  • Targeting AMPA receptors offers a promising therapeutic strategy against severe alphavirus-induced neurological disease.
  • Preventing immunopathologic damage is crucial for effective treatment, even if it involves modulating the immune response.
  • Further research is needed to balance antiviral defense with neuroprotection.